Overview

Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs

Status:
Unknown status

Trial end date:
2018-12-10

Target enrollment:

Participant gender:

Summary

This is open label, phase 1 clinical study to evaluate the safety, tolerability and pharmacokinetics of Elpida® in healthy subjects and patients with hepatic impairment (Child - Pugh Class А and B), as well as to assess the impact of food intake and drug-drug interactions in case of Co-administration with other antiviral drugs in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Viriom

Treatments:

Antiviral Agents
Dolutegravir
Elsulfavirine
Sofosbuvir